Document Detail


Growth kinetics of CD133-positive prostate cancer cells.
MedLine Citation:
PMID:  23138940     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: In the adult human prostate CD133 expression is thought to mark rare prostate epithelial stem cells and malignant tumor stem/initiating cells. Such putative stem cell populations are thought to proliferate slowly, but possess unlimited proliferative potential. Based on this, we hypothesized that CD133(pos) prostate cancer cells proliferate slower than CD133(neg) cells.
METHODS: Human prostate cancer cell lines were analyzed for CD133 expression and DNA content using flow cytometry. Rates of cell division and DNA synthesis were determined using CFSE cell tracing and BrdU uptake, respectively. Changes in cell cycle distribution and the percentage of CD133(pos) cells were assayed under conditions of different cell density and AR-pathway modulation. Lastly, we over-expressed lentiviral CD133 to measure whether CD133 regulates the cell cycle.
RESULTS: The cell cycle distribution differs between CD133(pos) and CD133(neg) cells in all three human prostate cancer cell lines studied. CD133(pos) cells have a greater proportion of cells in G2 and proliferate faster than CD133(neg) cells. High cell density increases the percentage of CD133(pos) cells without changing CD133(pos) cell cycle progression. Treatment with the AR agonist R1881, or the anti-androgen MDV3100, significantly changed the percentage and proliferation of CD133(pos) cells. Finally, ectopic over-expression of CD133 had no effect on cell cycle progression.
CONCLUSIONS: Contrary to our hypothesis, we demonstrate that CD133(pos) cells proliferate faster than CD133(neg) cells. This association of CD133 expression with increased cell proliferation is not directly mediated by CD133, suggesting that surface CD133 is a downstream target gene of an undefined pathway controlling cell proliferation.
Authors:
Edwin E Reyes; Stefan K Kunovac; Ryan Duggan; Steven Kregel; Donald J Vander Griend
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't     Date:  2012-11-08
Journal Detail:
Title:  The Prostate     Volume:  73     ISSN:  1097-0045     ISO Abbreviation:  Prostate     Publication Date:  2013 May 
Date Detail:
Created Date:  2013-04-15     Completed Date:  2013-06-27     Revised Date:  2014-06-09    
Medline Journal Info:
Nlm Unique ID:  8101368     Medline TA:  Prostate     Country:  United States    
Other Details:
Languages:  eng     Pagination:  724-33     Citation Subset:  IM    
Copyright Information:
Copyright © 2012 Wiley Periodicals, Inc.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Androgen Antagonists / pharmacology
Antigens, CD / metabolism*
Cell Cycle
Cell Line, Tumor
Flow Cytometry
Glycoproteins / metabolism*
Humans
Kinetics
Male
Peptides / metabolism*
Prostate / metabolism,  pathology*
Prostatic Neoplasms / metabolism,  pathology*
Real-Time Polymerase Chain Reaction
Grant Support
ID/Acronym/Agency:
AI07090-31/AI/NIAID NIH HHS; P50 CA090386/CA/NCI NIH HHS; T32 CA009594/CA/NCI NIH HHS; T32-CA09594/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/AC133 antigen; 0/Androgen Antagonists; 0/Antigens, CD; 0/Glycoproteins; 0/Peptides

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  ?-tocotrienol enhances the chemosensitivity of human oral cancer cells to docetaxel through the down...
Next Document:  Studying recombination in mouse oocytes.